×
About 1,770 results

ALLMedicine™ Cardiovascular Risk Reduction Center

Research & Reviews  497 results

Review of recent clinical trials and their impact on the treatment of hypercholesterole...
https://doi.org/10.1016/j.pcad.2022.11.011
Progress in Cardiovascular Diseases; Parham JS, Goldberg AC

Nov 19th, 2022 - Cardiovascular disease is the leading cause of death in the United States with incidence expected to increase in the coming decades. Recent years have produced a variety of new and novel therapeutics aimed at reducing the global burden of cardiova...

Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic ...
https://doi.org/10.1016/j.jacc.2022.08.802
Journal of the American College of Cardiology; Mahfoud F, Mancia G et. al.

Nov 11th, 2022 - Renal denervation (RDN) has been shown to lower blood pressure (BP), but its effects on cardiovascular events have only been preliminarily evaluated. Time in therapeutic range (TTR) of BP is associated with cardiovascular events. This study sought...

Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors.
https://doi.org/10.1016/j.atherosclerosis.2022.10.010
Atherosclerosis Safarova MS, Kullo IJ

Nov 8th, 2022 - Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors.|2022|Safarova MS,Kullo IJ,|

NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US popu...
https://doi.org/10.1186/s12933-022-01671-w
Cardiovascular Diabetology; Ciardullo S, Rea F et. al.

Nov 8th, 2022 - Even though hyperglycemia is a well-known cardiovascular risk factor, the absolute risk of cardiovascular events varies to a great extent within each glycemic category. The aim of this study is to evaluate whether N-terminal pro-B natriuretic pept...

Pharmacist-Managed Diabetic Retinopathy in Hispanic/LatinX Population.
https://doi.org/10.1177/08971900221136897
Journal of Pharmacy Practice; Patel J, Gonzalvo JD et. al.

Nov 4th, 2022 - There are three major microvascular complications of diabetes, retinopathy, nephropathy, and neuropathy, among which diabetic retinopathy (DR) is the most common. Several studies suggest that the Hispanic/LatinX population exhibit the highest case...

see more →

Guidelines  6 results

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545583
Journal of the American College of Cardiology; Das SR, Everett BM et. al.

Aug 11th, 2020 - 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.|2020|Das SR,Everett BM,Birtcher KK,Brown...

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk R...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560953
Journal of the American College of Cardiology; Das SR, Everett BM et. al.

Dec 1st, 2018 - 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consen...

Meditation and Cardiovascular Risk Reduction: A Scientific Statement From the American ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721815
Journal of the American Heart Association; Levine GN, Lange RA et. al.

Oct 1st, 2017 - Despite numerous advances in the prevention and treatment of atherosclerosis, cardiovascular disease remains a leading cause of morbidity and mortality. Novel and inexpensive interventions that can contribute to the primary and secondary preventio...

Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" ...
https://doi.org/10.1016/j.numecd.2016.11.122
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Pirro M, Vetrani C et. al.

Dec 14th, 2016 - Evidence showed that LDL-cholesterol lowering is associated with a significant cardiovascular risk reduction. The initial therapeutic approach to hypercholesterolemia includes dietary modifications but the compliance to recommendations is often in...

The most important meal of the day: why children skip breakfast and what can be done ab...
https://doi.org/10.3928/00904481-20130823-10
Pediatric Annals; Jackson LW

Sep 3rd, 2013 - We all experience that morning rush to get somewhere - to work, to school, or to complete a number of important errands before we reach those final destinations. Many adults skip meals for a variety of reasons. Children and teenagers are no differ...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  61 results

Lifestyle Intervention for Young Adults With Serious Mental Illness
https://clinicaltrials.gov/ct2/show/NCT02815813

Oct 14th, 2022 - The objective of this study is to evaluate the effectiveness of a group-based lifestyle intervention (PeerFIT) supported by mobile health (mHealth) technology and social media to promote weight loss and improved fitness in young adults with seriou...

Effects of Life Style Intervention Manual in Pre Hypertensive Sedentary Population
https://clinicaltrials.gov/ct2/show/NCT04841902

Apr 19th, 2022 - Adoption of healthy lifestyles by all persons is critical for the prevention of high BP and is an indispensable part of the management of those with hypertension. Weight loss of as little as 10 lbs (4.5 kg) reduces BP and/or prevents hypertension ...

Lifestyle Intervention Plus Emotion Regulation Group Intervention Impact on Women's Cardiovascular Risk Reduction
https://clinicaltrials.gov/ct2/show/NCT03167489

Apr 18th, 2022 - Group lifestyle interventions (LI) have documented efficacy in improving cardiovascular disease (CVD) risk factors, however, many fail to demonstrate outcome maintenance. Existing LIs primarily focus on behavioral regulation, neglecting to address...

SHOWME-PAD (Peripheral Artery Disease)
https://clinicaltrials.gov/ct2/show/NCT03190382

Apr 8th, 2022 - Peripheral arterial disease (PAD) is a burdensome condition that affects 10% of the population and increases to 15-20% among those ≥70 years. In PAD, the underlying pathophysiologic process, atherosclerosis, presents itself as blockages in patient...

Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD
https://clinicaltrials.gov/ct2/show/NCT03649204

Mar 14th, 2022 - Peripheral arterial disease (PAD), a disabling condition, affects 800,000 Canadians. People with PAD suffer from poor quality of life due to leg pain, which makes walking difficult. They also have a high risk of heart disease. In November of 2017,...

see more →

News  141 results

Stroke Management: There’s an App for That
https://www.medscape.com/viewarticle/982914

Oct 24th, 2022 - In the management of acute and chronic stroke, smartphone apps enhance communication between first responders and waiting hospital staff and reduce door-to-needle time, according to a literature review. Dr Fabio Pilato "In clinical practice, guide...

Evaluation of a Pharmacist-Driven Ambulatory Aspirin Deprescribing Protocol
https://www.mdedge.com/fedprac/article/258641/hospital-medicine/evaluation-pharmacist-driven-ambulatory-aspirin
Katherine Rothbauer, PharmDa, Magdalena Siodlak, PharmD, BCACP et. al.

Oct 14th, 2022 - The use of low-dose aspirin for the primary prevention of cardiovascular disease (CVD) morbidity and mortality continues to be controversial, particularly for older adults. Recently published, robust randomized controlled trials have revealed less.

ADA-EASD: More Holistic Approach Needed for Hyperglycemia Management
https://www.medscape.com/viewarticle/975212

Jun 23rd, 2022 - This transcript has been edited for clarity. In the 2022 Management of Hyperglycemia consensus statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), the focus has shifted. Regarding t...

A Brave New World in Type 2 Diabetes Treatment and Beyond
https://www.medscape.com/viewarticle/963270

Mar 22nd, 2022 - This transcript has been edited for clarity. Silvio Inzucchi, MD: Welcome to Medscape InDiscussion. I'm your host, Dr Silvio Inzucchi from Yale School of Medicine. Today we're talking about cardiovascular effects of type 2 diabetes medications and...

Full-press Therapy Rare in Diabetes With ASCVD
https://www.medscape.com/viewarticle/968881

Feb 19th, 2022 - A high percentage of people with type 2 diabetes also have atherosclerotic cardiovascular disease (ASCVD), but fewer than 1 in 20 get the triumvirate of evidence-based medications – drugs to lower cholesterol, blood pressure, and glucose levels – ...

see more →